INCREASED EXPRESSION OF INTERFERON RELATED GENES IN THE BONE MARROW MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES
EHA Library, Miyoung Kim, 53741
CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES.
EHA Library, Zuzana Zemanova, 53743
CIRCULATING SERUM MICRORNA-21 PREDICTS SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
EHA Library, Jung Yeon Lee, 53745
ANTI-ERYTHROBLAST AUTOIMMUNITY IN EARLY MYELODYSPLASTIC SYNDROMES: ENHANCEMENT OF EPO/EPO-R SYSTEM AND PRO-APOPTOTIC EFFECT
EHA Library, Anna Zaninoni, 53746
INDEPENDENT MULTICENTRIC STUDY ON THE INTEREST OF OGATA SCORE AND OF CD5, CD7 AND CD56 IN MDS AND MDS/MPS IN REAL LIFE.
EHA Library, Estelle Guerin, 53750
POSSIBLE PREVENTIVE ROLE OF CXCR4 AND ACTIVE CASPASE 3 IN LEUKEMIC EVOLUTION OF MYELODYSPLASTIC SYNDROMES
EHA Library, Veselka Nikolova, 53752
NEW GERMLINE TERT GENE MUTATIONS IN APLASTIC ANEMIA / HYPOCELLULAR MYELODYSPLASTIC SYNDROMES
EHA Library, Caterina Matteucci, 53753
IS THERE A RELATIONSHIP BETWEEN BONE MARROW CYTOMORPHOLOGY AND FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES?
EHA Library, Estelle Guerin, 53754
MOLECULAR CYTOGENETIC CHARACTERIZATION OF t(2;5)(p16.2;q33.1) LEADING TO PDGFRB/SPTBN1 GENE FUSION IN A CASE OF MDS RESPONSIVE TO IMATINIB MESYLATE
EHA Library, Daphne Koumbi, 53755
THE INTERPLAY BETWEEN OXIDATIVE STRESS AND EPIGENETIC PROFILE IN MYELOID NEOPLASIAS
EHA Library, Ana Cristina Gonçalves, 53756
IMMUNE SURVEILLANCE IMPACTS PROGNOSIS: REGULATORY T CELLS AND PROGENITOR B CELLS ARE INDEPENDENT PREDICTORS OF SURVIVAL IN LOW AND INTERMEDIATE RISK MDS
EHA Library, Josephine Kahn, 53757
DEFERASIROX CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS. A 'REAL WORLD' REPORT FROM TWO REGIONAL ITALIAN REGISTRIES : GRUPPO ROMANO MIELODISPLASIE AND REGISTRO BASILICATA
EHA Library, Luca Maurillo, 53758
THE INCIDENCE OF COMORBIDITIES AT THE TIME OF DIAGNOSIS IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES: OVERVIEW THROUGH THE 'REL' ('RETE EMATOLOGICA LOMBARDA') DISEASE REGISTRY
EHA Library, Marta Riva, 53759
MYOCARDIAL TISSUE CHARACTERIZATION BY CARDIAC MR IMAGING IN MYELODYSPLASTIC SYNDROMES
EHA Library, Alessia Pepe, 53760
PRE AND POST-TREATMENT SERUM FERRITIN LEVELS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES RECEIVING ERYTHROPOIESIS STIMULATING AGENTS
EHA Library, Heather Leitch, 53761
VALIDATION OF LOW RISK PROGNOSTIC SCORING SYSTEM (LR-PSS) IN 318 PATIENTS WITH LOWER RISK IPSS MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER.
EHA Library, Helena Pomares Marin, 53762
MRI SURVEY IN TRANSFUSION-DEPENDENT AND NON-TRANSFUSION-DEPENDENT MDS PATIENTS
EHA Library, Alessia Pepe, 53763
THE IMPACT OF TRANSFUSION DEPENDENCY ON THE OUTCOME OF PATIENTS WITH VERY LOW AND LOW RISK MYELODYSPLASTIC SYNDROME ACCORDING TO THE IPSS-R.
EHA Library, Montserrat Arnan, 53764
CALRETICULIN MUTATION WAS RARELY DETECTED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
EHA Library, Hsin-An Hou, 53765
DEVELOPMENT OF A HIGH RESOLUTION MELTING CURVE ANALYSIS SCREENING TEST FOR SRSF2 SPLICING FACTOR GENE MUTATIONS.
EHA Library, Eduardo Garza, 53768
GLUTATHIONE S-TRANSFERASE P1 (GSTP1) PROMOTER HYPERMETHYLATION IN MDS
EHA Library, Constantina Sambani, 53770
DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS
EHA Library, Ana Cristina Gonçalves, 53772
IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME
EHA Library, Michele Cea, 53773
BONE MARROW CD14+ CELLS SHOW DIFFERENT TRANSCRIPTIONAL PROFILES IN MULTIPLE MYELOMA (MM) AS COMPARED TO SMOLDERING MM AND MGUS: OVEREXPRESSION OF IL-21R AND ITS INVOLVEMENT IN OSTEOCLASTOGENESIS.
EHA Library, Nicola Giuliani, 53774
LONG-TERM RESULTS OF THE GIMEMA VEL-03-096 TRIAL IN MULTIPLE MYELOMA PATIENTS RECEIVING VTD CONSOLIDATION AFTER ASCT: IMPACT OF MRD KINETICS ON DURATION OF RESPONSE AND OVERALL SURVIVAL
EHA Library, Simone Ferrero, 53776
ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS
EHA Library, Alejandra Leivas, 53778
CIRCULATING MIR-34A AND MIR-130A AS BIOMARKERS OF EXTRAMEDULLARY DISEASE
EHA Library, Lenka Kubiczkova, 53779
DOES CHARACTERISTIC PHENOTYPE FOR PLASMA CELL LEUKAEMIA EXIST?
EHA Library, Lucie Rihova, 53781
GENE EXPRESSION PROFILING AND COPY NUMBER ALTERATIONS OF CIRCULATING CLONOTYPIC B CELLS OF MULTIPLE MYELOMA NEWLY DIAGNOSED PATIENTS REVEALS PATHWAYS POTENTIALLY INVOLVED IN THE DISEASE PERSISTENCE
EHA Library, Marina Martello, 53782
CAN GENOME ARRAY SCREENING REPLACE FISH AS A FRONT-LINE TEST IN MULTIPLE MYELOMA?
EHA Library, Katya Gancheva, 53783
COMPARATIVE STUDY OF GENE EXPRESSION PROFILING BETWEEN ASYMPTOMATIC AND SYMPTOMATIC WALDENSTROM\'S MACROGLOBULINEMIA PATIENTS
EHA Library, Cristina Jimenez, 53784
TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA
EHA Library, Mariateresa Fulciniti, 53785
DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS
EHA Library, Eli Muchtar, 53786
HSP90 INHIBITOR-DRUG CONJUGATES (HDC) WITH ANTITUMOR AGENTS TARGETING HEMATOLOGICAL MALIGNANCES
EHA Library, Patricia Rao, 53787
TOLL-LIKE RECEPTOR ACTIVATION PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL BY SUPPRESSION OF ENDOPLASMIC RETICULUM STRESS FACTOR CHOP
EHA Library, Efstathios Kastritis, 53788
ENDOPLASMIC RETICULUM STRESS-RELATED GENE EXPRESSION CAN PREDICT RESPONSE TO BORTEZOMIB IN MYELOMA
EHA Library, Narita Tomoko, 53789
MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS – TOWARDS PERSONALIZED MYELOMA THERAPY
EHA Library, Maria Gkotzamanidou, 53790
TARGETING ANGIOGENESIS IN MULTIPLE MYELOMA: A POSSIBLE ROLE FOR EPHA3 AND A SPECIFIC MONOCLONAL ANTIBODY
EHA Library, Antonella Caivano, 53792
INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Library, Andrzej J. Jakubowiak, 53793
THE USE OF SINGLE AGENT ZOLEDRONIC ACID PREVENTS THE DEVELOPMENT OF BONE DISEASE COMPLICATIONS IN MYELOMA PATIENTS WITH ASYMPTOMATIC RELAPSES WITH NO DEMONSTRATED EFFECT ON SYMPTOMS PROGRESSION
EHA Library, Ramon Garcia-Sanz, 53794
LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS
EHA Library, Valeria Magarotto, 53795
SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA.
EHA Library, Torben Plesner, 53796
POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL
EHA Library, PAUL RICHARDSON, 53797
Preliminary pre-randomization results from a phase 3 study of front-line subcutaneous bortezomib-based induction and consolidation in transplantation-eligible multiple myeloma patients
EHA Library, Noemi Horvath, 53799
GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.
EHA Library, Roberto Mina, 53800
Oral investigational proteasome inhibitor ixazomib plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma
EHA Library, PAUL RICHARDSON, 53801
DOSE-DEPENDENT EFFICACY OF DARATUMUMAB AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Library, Henk Lokhorst, 53802
EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EHA Library, Chiara Cerrato, 53803
RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA
EHA Library, Noopur Raje, 53804
A PHASE 2 STUDY OF CIRCULARLY PERMUTED TRAIL (CPT) PLUS THALIDOMIDE AND DEXAMETHASONE VERSUS THALIDOMIDE AND DEXAMETHASON IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Library, Wenming Chen, 53805
PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)
EHA Library, PAUL RICHARDSON, 53806
POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WITH DELETION DEL(17P) AND/OR TRANSLOCATION T(4;14).
EHA Library, Xavier Leleu, 53807
PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY
EHA Library, Michele Cavo, 53808
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE FIRST TRIAL
EHA Library, Michel Delforge, 53809
MM-003, A PHASE 3 STUDY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH
EHA Library, Jesús San Miguel, 53810
OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
EHA Library, Efstathios Kastritis, 53812
BORTEZOMIB COMBINATION THERAPY, AND SUBSEQUENT BORTEZOMIB RE-TREATMENT, IS A USEFUL TREATMENT STRATEGY FOR MULTIPLE MYELOMA PATIENTS WITH RAS MUTATIONS
EHA Library, Dean Smith, 53813
EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSE/REFRACTORY MULTIPLE MYELOMA (RRMM): PATTERNS OF ANTITHROMBOTIC PROPHYLAXIS IN A LARGE COHORT OF MM PATIENTS TREATED WITH LENALIDOMIDE
EHA Library, Barbara Gamberi, 53814
Long-term follow-up of a randomized phase 2 study of bortezomib, thalidomide, and dexamethasone, with or without cyclophosphamide, as induction therapy for patients with previously untreated multiple myeloma
EHA Library, Heinz Ludwig, 53815
A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Ajai Chari, 53816
A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Thomas Martin, 53819
Monoclonal gammopathy of undetermined significance is associated with inferior survival: a population-based study
EHA Library, Ebba Lindqvist, 53821
INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA
EHA Library, Kai Riecke, 53822
MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS: A POPULATION BASED-STUDY
EHA Library, Gudbjörg Jónsdóttir, 53824
BORTEZOMIB OR THALIDOMIDE INCORPORATED INTO AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NOVEL AGENT-BASED TREATMENTS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A CASE-MATCH COMPARISON
EHA Library, Paola Tacchetti, 53825
INTRACELLULAR CALCIUM DEPOSITS AND STORE OPERATED CALCIUM ENTRY IN CD34+ CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING A CALR MUTATION
EHA Library, Vittorio Rosti, 53834
VEGF-INDUCED CA2+ SIGNALS ARE DERANGED IN ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING JAK2 MUTATIONS
EHA Library, Francesco Moccia, 53835
LOW RATE OF CALR MUTATIONS IN REFRACTORY ANAEMIA WITH RING SIDEROBLASTS AND MARKED THROMBOCYTOSIS
EHA Library, Francois Girodon, 53837
GATA1 IS OVEREXPRESSED IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND IT IS NORMALIZED BY ANAGRELIDE TREATMENT.
EHA Library, Ciro Rinaldi, 53838
IMPORTANCE OF CALR MUTATIONS IN THE DIAGNOSIS OF PRIMARY MYELOFIBROSIS.
EHA Library, Lurdes Zamora Plana, 53839
MOUSE LEUKEMIC TRANSFORMATION IN PMF XENOGRAFT MODEL REVEALS PARACRINE REGULATION IN DISEASE PROGRESSION
EHA Library, Ioanna Triviai, 53841
CYTOGENETIC INVESTIGATION OF G-CSF-STIMULATED PERIPHERAL BLOOD IN PATIENTS WITH PRIMARY MYELOFIBROSIS
EHA Library, Rostyslav Lozynskyy, 53842
CHARACTERIZATION OF MPL-MUTATED MYELOID NEOPLASMS: A REVIEW OF 224 MPL+ CASES
EHA Library, Keming Lin, 53843
DEREGULATION OF MICRORNA146B-1 IS ASSOCIATED WITH MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Jung Sook Ha, 53844
HIGH THROUGHPUT SCREENING ON PERIPHERAL BLOOD CD34 CELLS WITH A FLOW CYTOMETRY AUTOMATED PLATFORM (EXVITECH), TO IDENTIFY SENSITIVITY TO RUXOLITINIB IN MYELOFIBROSIS PATIENTS
EHA Library, Alicia Arenas, 53845
HEMATOPOIETIC PROGENITOR CELLS EXPRESSING VE-CADHERIN ARE DETECTABLE IN THE SPLEEN OF PATIENTS WITH MYELOFIBROSIS AND ARE IN CLOSE CONTACT WITH MICROVESSELS
EHA Library, Vittorio Rosti, 53846
EVALUATION OF THE ASSOCIATION BETWEEN JAK2 46/1 HAPLOTYPE AND MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Jung Sook Ha, 53847
OUTCOME OF JAK2/MPL/CALR TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Library, Victoria Panagiota, 53850
CLINICAL CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASM WITH CALRETICULIN MUTATIONS
EHA Library, Tunde Krahling, 53854
JAK2 V617F ALLELE BURDEN AND VASCULAR COMPLICATION OCCURRENCE RISK IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Martyna Borowczyk, 53855
RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST–POLYCYTHEMIA VERA MYELOFIBROSIS OR POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
EHA Library, Alessandro M. Vannucchi, 53856
UTILITY OF BONE MARROW HISTOLOGY AND IMMUNOHISTOCHEMISTRY IN THE DIAGNOSTIC WORK-UP OF EOSINOPHILIA OF UNKNOWN SIGNIFICANCE
EHA Library, Georgia Metzgeroth, 53857
INFLUENCE OF IL-28B AND IL-6 GENETIC POLYMORPHISM ON IFN-ALFA TREATMENT OUTCOME IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL TROMBOCYTHEMIA
EHA Library, Marie Lindgren, 53858
DYNAMICS OF CALR MUTANT ALLELE BURDEN IN ESSENTIAL THROMBOCYTHEMIA PATIENTS
EHA Library, Beatriz Bellosillo, 53859
RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL
EHA Library, Adam Mead, 53860
TREATMENT OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH PEGYLATED INTERFERON ALPHA-2A: A PROSPECTIVE MONOCENTER COHORT STUDY.
EHA Library, Valerio De Stefano, 53861
SPECIFIC DETECTION OF CALR-MUTATED MYELOPROLIFERATIVE NEOPLASMS BY IMMUNOSTAINING
EHA Library, Giada Rotunno, 53862
MICROARRAY ANALYSIS OF CHROMOSOME 11Q IN A GROUP OF AGGRESSIVE LYMPHOMA: THE PARTIAL DUPLICATION OF 11Q AS A CYTOGENETIC MARKER OF SUBSET OF THE GREY ZONE BETWEEN BURKITT'S (BL) AND DIFFUSE LARGE B-C
EHA Library, Beata Grygalewicz, 53864
CLONAL EVOLUTION IN BURKITT LYMPHOMA/LEUKEMIA
EHA Library, Sietse Aukema, 53867
HIGH EXPRESSION OF MIRNA-199A_1 AND MIRNA-497_1 IS ASSOCIATED WITH BETTER OVERALL SURVIVAL IN AGGRESSIVE NON-HODGKIN´S LYMPHOMA
EHA Library, Katharina Troppan, 53871
LOSS OF BCL2L12 PROTEIN EXPRESSION PREDICTS RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS CONVENTIONAL CHEMOTHERAPY (CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AN
EHA Library, Sotirios Papageorgiou, 53872
NR4A3-MEDIATED APOPTOSIS SUPPRESSES LYMPHOMAGENESIS IN A XENOGRAFT MOUSE MODEL
EHA Library, Alexander Deutsch, 53873
CONSTITUTIVE ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS A NOVEL THERAPEUTIC TARGET IN DIFFUSE LARGE B-CELL LYMPHOMA.
EHA Library, Enrico Derenzini, 53875
KINOME REPROGRAMMING IN DLBCL BY THE BTK-SPECIFIC INHIBITOR ONO-4059 HIGHLIGHTS SYNERGISTIC COMBINATIONS FOR CLINICAL APPLICATION
EHA Library, Ryohei Kozaki, 53877
PRECLINICAL EVALUATION OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-201, FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
EHA Library, Aleksandra Stanczak, 53878
Computerized image analysis of the Ki-67 proliferation index for risk stratification of patients with mantle cell lymphoma
EHA Library, Yngvild Nuvin Blaker, 53881
Flow cytometric analysis of SOX11: a new diagnostic method for distingusing B-CLL from MCL
EHA Library, Martin Lord, 53882
AMC AND ALC IN FOLLICULAR LYMPHOMA: PROGNOSTIC ROLE IN PFS
EHA Library, Stefano Sacchi, 53883
BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R-BM) INDUCTION PLUS RITUXIMAB CONSOLIDATION IN ELDERLY DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA: FINAL RESULTS OF A STUDY BY FONDAZIONE ITALIANA LINFOMI
EHA Library, Carola Boccomini, 53884

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings